BioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 230,800 Shares of Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 230,800 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total value of C$2,566,496.00.

BioSyent Trading Up 4.0 %

BioSyent stock opened at C$11.70 on Tuesday. BioSyent Inc. has a 1 year low of C$8.24 and a 1 year high of C$11.74. The firm’s 50 day moving average price is C$11.05 and its 200-day moving average price is C$10.27. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. The stock has a market cap of C$135.60 million, a P/E ratio of 19.50 and a beta of 0.93.

BioSyent (CVE:RX) last announced its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C$0.13. The company had revenue of C$8.95 million for the quarter, compared to the consensus estimate of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. On average, equities analysts predict that BioSyent Inc. will post 0.6944444 earnings per share for the current fiscal year.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.